Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes

Abstract

Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (ClinicalTrials.gov number, NCT00139815.).